Skip to main content

Search

Reset all filters
135 Result(s)
Sort by

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot

Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot

• Boehringer Ingelheim Animal Health Canada Inc. launches a unique vaccine combination that protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv) in one shot
ABIC-COPD

ABIC-COPD

Discover the ABIC Fund, developed to advance health innovation projects in the area of respiratory diseases, like COPD, for Alberta-based investigators.